Peptide directory

◇Not a peptide·Small molecule

A small-molecule compound that researchers and self-experimenters study for its effects on metabolism, body composition, cellular energy, and healthy aging. Often discussed as a tool for understanding and potentially optimizing metabolic flexibility through NNMT inhibition.

A synthetic fragment of growth hormone designed to isolate GH's fat-mobilizing effects without its growth-promoting or blood-sugar-altering activity — a tool researchers and self-experimenters study for body composition and joint health.

A stable 15-amino-acid peptide fragment derived from a protein in human gastric juice, widely studied in preclinical models for tissue protection and repair across gut, tendon, muscle, and vascular tissue.

A parenteral preparation of small peptides and amino acids derived from porcine brain protein, used clinically for decades across stroke, dementia, and traumatic brain injury recovery in many countries outside the US.

A synthetic analog of growth-hormone-releasing hormone (GHRH) engineered for extended half-life, studied for prolonged stimulation of pulsatile GH and IGF-1 release — a tool researchers and self-experimenters use to explore their own endocrine biology.

A compounded blend pairing a short-acting GHRH analog (CJC-1295 without DAC) with the selective GHS peptide Ipamorelin — popular in self-experimentation for its goal of mimicking physiologic, pulsatile growth hormone release rather than sustained elevation.

A nine-amino-acid neuropeptide first isolated in 1977 from the cerebral venous blood of slow-wave-sleeping rabbits — a decades-long scientific puzzle studied for effects on sleep, stress tolerance, and neuroendocrine signaling.

A synthetic tetrapeptide derived from the pineal preparation Epitalamin, studied for decades in Russian research for effects on telomerase activity, melatonin rhythm, and age-related biomarkers.

A naturally occurring copper-binding tripeptide studied for skin regeneration, hair biology, and extracellular matrix remodeling, with one of the most mature cosmetic and wound-healing research literatures in the peptide space.

A compounded peptide blend typically combining GHK-Cu, larazotide acetate, and additional peptides — formulated around the intersection of skin quality, hair support, and gut-barrier integrity, and studied by self-experimenters interested in that multi-tissue angle.

An endogenous tripeptide and the body's most abundant intracellular antioxidant, used clinically as an IV adjunct in hepatic, dermatologic, and neurological contexts and studied for oxidative stress and detoxification biology.

A modified analog of insulin-like growth factor 1 engineered with a dramatically longer active window, widely used as a research reagent for studying anabolic signaling, muscle biology, and the downstream effects of the GH/IGF-1 axis.

A synthetic pentapeptide that gently nudges the pituitary to release its own growth hormone — studied for clean, selective GH pulses without the cortisol or prolactin effects of earlier secretagogues.

A compounded peptide blend that combines KPV, GHK-Cu, BPC-157, and TB-500 — studied individually for tissue repair, inflammation modulation, and skin quality, and packaged together in compounding-pharmacy contexts.

A short tripeptide derived from α-melanocyte-stimulating hormone, studied for anti-inflammatory effects in gut, skin, and ocular tissue — without the pigmentation activity of its parent hormone.

The only human cathelicidin antimicrobial peptide — a 37-amino-acid fragment of hCAP-18 studied for its broad antimicrobial activity, wound-healing signaling, and immunomodulatory effects across preclinical and early clinical work.

A synthetic pan-melanocortin agonist originally developed at the University of Arizona as a sunless-tanning research candidate and later studied for central effects on sexual arousal and appetite regulation.

A 16-amino-acid peptide encoded inside mitochondrial DNA itself, studied for effects on insulin sensitivity, exercise adaptation, and age-related metabolic decline — a fascinating window into mitochondrial-nuclear signaling.

◇Not a peptide·Coenzyme

A central coenzyme in cellular energy, DNA repair, and sirtuin biology, studied extensively in aging and metabolic health — most commonly researched via oral precursors like nicotinamide riboside (NR) and NMN.

An FDA-approved synthetic cyclic heptapeptide (Vyleesi) that acts on central melanocortin receptors to treat hypoactive sexual desire disorder in premenopausal women — the first approved centrally-acting treatment for this indication.

An investigational Eli Lilly triple agonist at the GLP-1, GIP, and glucagon receptors, currently in Phase 3 development with some of the largest weight-loss effect sizes reported in clinical pharmacotherapy.

A synthetic heptapeptide analog of the natural immunomodulator tuftsin, studied for its anxiolytic, immunomodulatory, and neurotrophic effects — and registered as an anti-anxiety pharmaceutical in Russia.

A long-acting GLP-1 receptor agonist originally developed for type 2 diabetes and now FDA-approved for chronic weight management, with an active research pipeline in cardiometabolic, liver, and neurological disease.

A synthetic heptapeptide derived from an ACTH fragment, studied for neurotrophic, cognitive, and neuroprotective effects — and registered as an intranasal pharmaceutical in Russia for stroke and cognitive indications.

A synthetic analog of the active N-terminal region of human growth-hormone-releasing hormone, historically FDA-approved for pediatric GH deficiency and studied as a more physiologic approach to restoring pulsatile GH secretion.

A synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, studied in Phase 2–3 programs for primary mitochondrial disease, Barth syndrome, and dry age-related macular degeneration.

A short synthetic peptide corresponding to an active region of thymosin β4, studied in preclinical models of wound healing, cardiac repair, and tissue regeneration — often compared with, but distinct from, full-length Tβ4.

A stabilized synthetic analog of GHRH, FDA-approved for reducing abdominal fat in HIV-associated lipodystrophy and actively studied for visceral adiposity, liver disease, and cognitive endpoints in related contexts.

A 28-amino-acid immunomodulatory peptide naturally produced by the thymus, registered as a pharmaceutical in over 30 countries (as Zadaxin/Thymalfasin) for hepatitis B, hepatitis C, and immune-adjunct use — not FDA-approved in the United States.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, producing the largest Phase 3 weight-loss effects reported to date in an FDA-approved pharmacotherapy.

A compounded blend combining BPC-157 and TB-500 — two research peptides with preclinical tissue-repair literature — marketed as a "recovery stack" rather than a standardized pharmaceutical, with the research picture derived almost entirely from component-level studies.